PureTech Acquires Alivio and Adds Inflammatory Disease Program to Its Pipeline

Four years after launching Alivio Therapeutics, PureTech Health is reinstated its hydrogel player by acquiring the remaining 22% of the company.

Through the contract, PureTech add Alivio’s unique pipeline of inflammatory disease programs, including LYT-500, an oral treatment for inflammatory bowel disease (IBD).

There are a variety of IBD treatments, but each has its own challenges. Anti-inflammatory drugs do not work for everyone, but systemic immunosuppressive drugs can reduce the body’s immune surveillance, even though it reduces inflammation. When it comes to new biologics, they can be expensive and need to be injected, which is not always attractive to the patient.

Relation: PureTech Focuses on Long-Term Clinical Trials of COVID-19 Complications

Alivio, and now PureTech, are looking to solve these problems. This technique is based on a hydrogel material designed to adhere to inflamed tissue but not to healthy tissue. There, the medicine is delivered according to the degree of inflammation. LYT-500 combines the cytokine interleukin 22 with anti-inflammatory drugs to address two major causes of IBD: disruption of the intestinal mucosal barrier and inflammation.

Through the contract, PureTech will also pick up LYT-503 / IMB-150 for interstitial cystitis, also known as bladder pain syndrome, which Alivio was developing at Imbrium Therapeutics. Both companies have positioned it as a non-opioid treatment for this condition.

The Alivio program participates in the treatment pipeline for various diseases such as neurological disorders, COVID-19, solid tumors and hematological malignancies. PureTech started by spinning the technology out to companies like Alivio, but the plan was always to develop its own pipeline, PureTech CEO and founder Daphne Zohar said in an interview earlier this year. I am.

Relation: Hydrogel delivery enables long-term “flare-responsive” arthritis treatment

Initially, PureTech identified new technologies and new potential medicines, but did not have the capital to develop them independently, Zohar said. Over the years, it has given the shares of the company it founded and, in some cases, royalties and more capital to cooperate. “About four years ago … we decided not to relinquish ownership of future programs,” Zohar said. PureTech Acquires Alivio and Adds Inflammatory Disease Program to Its Pipeline

Back to top button